Multiple endocrine neoplasia type 2 screening: Difference between revisions
No edit summary |
|||
Line 15: | Line 15: | ||
! style="padding: 0 5px; font-size: 95%; background: #DCDCDC" align=left | '''The DNA-based testing of the c-RET gene''' | ! style="padding: 0 5px; font-size: 95%; background: #DCDCDC" align=left | '''The DNA-based testing of the c-RET gene''' | ||
|- | |- | ||
| rowspan="1" style="font-size: 95%; padding: 0 5px; background: #F5F5F5" | ▸ Children with c-RET codon 609, 768, 790, 791, 804 and 891 mutations are more prone to less aggressive and slowly growing medullary thyroid cancer and a periodic [[pentagastrin]]-stimulated test with [[thyroidectomy]], at the first abnormal test result, has been recommended.<ref | | rowspan="1" style="font-size: 95%; padding: 0 5px; background: #F5F5F5" | ▸ Children with c-RET codon 609, 768, 790, 791, 804 and 891 mutations are more prone to less aggressive and slowly growing medullary thyroid cancer and a periodic [[pentagastrin]]-stimulated test with [[thyroidectomy]], at the first abnormal test result, has been recommended.<ref> Multiple endocrine neoplasia type2. Orphanet (30.10.2015). http://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=GB&Expert=653 Accessed on October, 30, 2015</ref> | ||
|- | |- | ||
| rowspan="1" style="font-size: 95%; padding: 0 5px; background: #F5F5F5" | ▸ Individuals with c-RET codon 609, 611, 618, 620, 630, 634, 790, V804L, 883, 918 or 922 mutations should be routinely screened for [[pheochromocytoma]] by annual determinations of fractionated urinary and free plasma [[metanephrine]]s and [[catecholamine]]s. | | rowspan="1" style="font-size: 95%; padding: 0 5px; background: #F5F5F5" | ▸ Individuals with c-RET codon 609, 611, 618, 620, 630, 634, 790, V804L, 883, 918 or 922 mutations should be routinely screened for [[pheochromocytoma]] by annual determinations of fractionated urinary and free plasma [[metanephrine]]s and [[catecholamine]]s. |
Revision as of 02:26, 5 October 2015
Multiple endocrine neoplasia type 2 Microchapters |
Differentiating Multiple endocrine neoplasia type 2 from other Diseases |
---|
Diagnosis |
Treatment |
Multiple endocrine neoplasia type 2 screening On the Web |
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 2 screening |
Directions to Hospitals Treating Multiple endocrine neoplasia type 2 |
Risk calculators and risk factors for Multiple endocrine neoplasia type 2 screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
According to the American Society of Clinical Oncology, screening for multiple endocrine neoplasia type 2 by RET gene testing is recommended for children with increased risk of multiple endocrine neoplasia type 2.
Screening
- The DNA-based testing of the c-RET gene is recommended for children with increased risk of multiple endocrine neoplasia type 2. It can be easily performed on a blood sample at any age. It offers the opportunity for early identification of the c-RET germline mutations, thus contributing to the reduction of morbidity and mortality of multiple endocrine neoplasia type 2 syndrome. In fact, the early recognition of the mutant gene carriers makes possible the prevention and cure of medullary thyroid cancer, by performing a prophylactic thyroidectomy before the clinical expression of the tumor. This test is also of importance to detect and thus, to reduce the risk of an unsuspected pheochromocytoma.
- Screening for multiple endocrine neoplasia type 2 include the following tests.
References
|